Drug intelligence / Profile preview

Clinpro Tooth Crème

Development stage: Phase 4
Lead developer: 3M
Modality: Small Molecules
Administration: Topical, Dental

Overview

**Clinpro Tooth Crème** is a non-prescription anti-cavity dentifrice developed by 3M and currently marketed by Solventum. It contains 0.21% sodium fluoride, providing 950 ppm fluoride ion, together with functionalized tri-calcium phosphate. During topical toothbrushing use, fluoride, calcium, and phosphate are delivered at the tooth surface to promote remineralization of demineralized enamel, increase acid resistance through fluorapatite formation, and help prevent dental caries and white spot lesions. The product is also designed to occlude exposed dentin tubules and may help reduce dentin hypersensitivity. ([solventum.com](https://www.solventum.com/en-us/home/f/b00005768/))

Brand names: Clinpro Tooth Crème
Other names: Clinpro Tooth Creme

Beyond the preview

Go deeper on Clinpro Tooth Crème.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clinpro Tooth Crème.

Explore the full profile